In 124 patients with dilated cardiomyopathy, symptoms of heart failure and ventricular arrhythmia at initial assessment were related to outcome a mean of 43 months later. Using life table analysis, the two-year mortality from progressive heart failure was 59 per cent (90 per cent symptoms, six per cent (1-11 per cent) for patients with class 2 symptoms and zero for patients with class 1 symptoms. The two-year mortality from sudden death was 18 per cent (5-32 per cent) for patients with class 3 symptoms, eight per cent (3-14 per cent) for patients with class 2 symptoms and seven per cent (0-17 per cent) for patients with class 1 symptoms. Sudden death was more frequent in patients with ventricular tachycardia or frequent ventricular ectopics, irrespective of the severity of heart failure (15 per cent (7-23 per cent) vs. three per cent (0-8 per cent) at two years). These findings suggest that patients with dilated cardiomyopathy and mild symptoms often have a benign clinical course. However, occult ventricular arrhythmia is associated with an increased risk of sudden death.

Download full-text PDF

Source

Publication Analysis

Top Keywords

patients class
20
class symptoms
20
heart failure
16
cent patients
16
cent
14
dilated cardiomyopathy
12
symptoms cent
12
sudden death
12
patients
8
patients dilated
8

Similar Publications

Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.

Ther Adv Neurol Disord

January 2025

Department of the Second Cadre Ward, General Hospital of Northern Theater Command, No. 83, Culture Road, Shenyang, Liaoning Province 110016, China.

Background: Dementia is a serious adverse event (AE) that requires attention in clinical practice. However, information on drug-induced dementia is limited. The U.

View Article and Find Full Text PDF

Introduction: Hypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM). Traditional treatments address symptoms but not the underlying disease mechanism, highlighting the need for novel therapies.

View Article and Find Full Text PDF

Background: Treatment guidelines recommend metformin as initial drug in many people with type 2 diabetes (T2D) and low risk of cardiovascular disease, with the possibility to switch to or add other drug classes. A decision aid (DA) could be useful to incorporate a patient's preferences in the decision of which drug class to choose. We developed such a DA and assessed the perspectives of people with T2D towards its comprehensibility and usability.

View Article and Find Full Text PDF

Aims: This retrospective cohort study aimed to investigate the efficacy of dual-chamber left Bundle branch pacing (LBBP) as an alternative therapy for heart failure patients with complete left bundle branch block (CLBBB) and indications for defibrillator with cardiac resynchronization therapy (CRT-D).

Methods: 34 patients met inclusion criteria were enrolled in the study. These criteria included a left ventricular ejection fraction (LVEF) of lower than 35%, a New York Heart Association functional class of II-IV, CLBBB meeting Strauss's criteria, intraventricular dyssynchrony, and confirmed correction of CLBBB during LBBP.

View Article and Find Full Text PDF

Background: HCV genotypes are 30-35% polymorphic at the nucleotide level, while subtypes within the same genotype differ by nearly 20%. Although previous studies have shown the immune escape potential of several mutations within the HCV proteins, little is known about the effect of genotype/subtype-specific gene polymorphism on T-cell immunity. Therefore, this study employed several methods to examine the impact of genotype/subtype-specific polymorphisms in Core, NS3, NS5A, and NS5B sequences on T cell epitope processing and HLA-epitope interactions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!